We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases. According to Ascendis, TransCon is a drug development platform that uses advanced chemistry to overcome known challenges in developing therapeutics
Factors including metabolic biomarkers, kidney function, gastrointestinal history, and personal medical goals should guide whether this therapy is right for you
US News and World Report selected his firm in 2010, 2011, 2012, 2013, 2014 and 2015 as one of the Best Law Firms in America, Woodward White, Inc
Multiple testing options with rapid results for COVID-19 exposure or symptoms
En inhibant la multiplication des virus, le glutathion aide mieux contrler l'infection et en rduire la gravit